HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Helen of Troy Q2

This article was originally published in The Rose Sheet

Executive Summary

Sea Breeze and Brut brands generated double-digit sales growth in the quarter, company announces during Oct. 11 earnings call. However, personal care net revenues declined 14.8% to $100.9 mil., due to "pressures to lower prices, additional competition on selected items and additional costs associated with trade promotions," firm says. Division may rebound next year with the launch of Sea Breeze Naturals, a line that will be targeted to older customers rather than the brand's traditionally younger audience, Helen of Troy notes. Company adds that sales of Brut in Mexico have been "very positive" since launching new products in the region (1"The Rose Sheet" April 25, 2005, p. 9). Second quarter net sales declined 7.7% to $130.4 mil., while net earnings fell 49.9% to $9.5 mil., impacted by challenging economic conditions and weak performance by personal care segment, firm says. Fiscal 2006 (ending Feb. 28) sales are expected to be in the range of $575 mil.-$590 mil., versus previous guidance of $615 mil.-$640 mil, according to Helen of Troy...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel